Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells - PubMed (original) (raw)

Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells

C J Eaves et al. Proc Natl Acad Sci U S A. 1993.

Abstract

Most primitive hematopoietic cells appear to be normally quiescent in vivo, whereas their leukemic counterparts in patients with chronic myeloid leukemia (CML) are maintained in a state of rapid turnover. This difference is also seen in the long-term culture system, where control of primitive hematopoietic progenitor proliferation is mediated by interactions of these cells with marrow-derived mesenchymal cells of the fibroblast lineage. We now show that exogenous addition of macrophage inflammatory protein 1 alpha (MIP-1 alpha) to normal long-term cultures can reversibly and specifically block the activation of "primitive" (high proliferative potential), but not "mature" (lower proliferative potential), progenitors in the adherent layer of these cultures. Moreover, addition of MIP-1 beta after primitive-progenitor activation can prevent the subsequent return of these cells to a quiescent state a few days later as shown previously in similar experiments using antibodies to transforming growth factor beta. This suggests that the level of MIP-1 alpha (or a related MIP-1 alpha agonist) produced in LTCs, like the level of transforming growth factor beta, may be necessary, but is not on its own sufficient, to mediate the inhibitory activity of the regulatory cells in the adherent layer. Addition of MIP-1 alpha to similar long-term cultures containing normal marrow adherent layers but supporting exclusively neoplastic (CML) hematopoiesis did not block the cycling of primitive neoplastic progenitors. A defect in the responsiveness of CML cells to MIP-1 alpha (or a similarly acting chemokine) would explain their deregulated proliferative behavior in this model and, by extrapolation to the in vivo setting, suggests a molecular mechanism whereby the leukemic clone may become amplified at the stem-cell level. In addition, these findings suggest approaches to the therapy of CML, using inhibitors such as MIP-1 alpha for the protection of primitive normal cells.

PubMed Disclaimer

Cited by

Human chemokines: enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice.
Broxmeyer HE, Cooper S, Hague N, Benninger L, Sarris A, Cornetta K, Vadhan-Raj S, Hendrie P, Mantel C. Broxmeyer HE, et al. Ann Hematol. 1995 Nov;71(5):235-46. doi: 10.1007/BF01744373. Ann Hematol. 1995. PMID: 7492626
Presence of P210bcrabl is associated with decreased expression of a beta chemokine C10 gene in a P210bcrabl-positive myeloid leukemia cell line.
Lane CM, Guo XY, Macaluso LH, Yung KC, Deisseroth AB. Lane CM, et al. Mol Med. 1999 Jan;5(1):55-61. Mol Med. 1999. PMID: 10072448 Free PMC article.
Role of macrophage inflammatory protein (MIP)-1α/CCL3 in leukemogenesis.
Baba T, Mukaida N. Baba T, et al. Mol Cell Oncol. 2014 Jul 15;1(1):e29899. doi: 10.4161/mco.29899. eCollection 2014. Mol Cell Oncol. 2014. PMID: 27308309 Free PMC article. Review.
Blast colony-forming cell binding from CML bone marrow, or blood, on stromal layers pretreated with G-CSF or SCF.
Gidáli J, László E, Halm G, Fehér I. Gidáli J, et al. Cell Prolif. 2002 Feb;35(1):1-7. doi: 10.1046/j.1365-2184.2002.00217.x. Cell Prolif. 2002. PMID: 11856174 Free PMC article.

References

1. Nature. 1982 Dec 23;300(5894):765-7 - PubMed
1. Blood. 1982 Apr;59(4):793-808 - PubMed
1. Cell. 1984 Jan;36(1):93-9 - PubMed
1. Blood. 1984 May;63(5):1172-7 - PubMed
1. J Clin Oncol. 1985 Feb;3(2):192-200 - PubMed

Unresponsiveness of primitive chronic myeloid leukemia cells to macrophage inflammatory protein 1 alpha, an inhibitor of primitive normal hematopoietic cells - PubMed (original) (raw)